Document:

Exhibit 10.8

                           PLACEMENT AGENCY AGREEMENT

         This Placement Agency Agreement (this  "Agreement") is made and entered
into as of May 17, 2005 (the "Effective  Date"),  by and between Intraop Medical
Corporation,  a Nevada  corporation (the "Company"),  and Stonegate  Securities,
Inc., a Texas corporation ("Stonegate").

         WHEREAS,  the Company desires to retain Stonegate as its  non-exclusive
placement agent, and Stonegate is willing to act in such capacity,  in each case
subject to the terms and conditions of this Agreement.

         NOW,  THEREFORE,  in  consideration  of the  premises  and  the  mutual
covenants  herein  contained,  the  Company  and  Stonegate  (each a "Party" and
collectively, the "Parties") hereby agree as follows:

1.   RETENTION OF STONEGATE; SCOPE OF SERVICES.

     (a)  Subject to the terms and  conditions  set forth  herein,  the  Company
          hereby retains Stonegate to act as the  non-exclusive  placement agent
          to the  Company  during the  Contract  Period (as defined in Section 2
          below), and Stonegate hereby agrees to be so retained.

     (b)  As the  non-exclusive  placement agent to the Company,  Stonegate will
          have the  non-exclusive  right during the Contract  Period to identify
          for  the  Company  prospective  purchasers,  each  of  whom  shall  be
          accredited  investors,  as such  term is  defined  in Rule  501 of the
          Securities  Act of 1933,  as  amended  (the  "Securities  Act")  (such
          prospective  purchaser being  collectively,  the "Purchasers" and each
          individually,  a  "Purchaser")  in one or  more  placements  (each,  a
          "Placement" and collectively,  the "Placements") of debt and/or equity
          securities  to be issued by the  Company,  the type and dollar  amount
          being as mutually  agreed to by the Company  and the  Purchasers  (the
          "Securities").

     (c)  Terms  of  the  Placements  shall  be as  set  forth  in  subscription
          documents,  including any stock  purchase or  subscription  agreement,
          escrow agreement,  registration  rights  agreement,  warrant agreement
          and/or other documents to be executed and delivered in connection with
          each  Placement  (collectively,  the  "Subscription  Documents").  The
          Placements   are   intended  to  be  exempt   from  the   registration
          requirements  of  the  Securities   Act,   pursuant  to  Regulation  D
          ("Regulation  D") of the rules and  regulations  of the Securities and
          Exchange Commission (the "SEC") promulgated under the Securities Act.

                                       1
<PAGE>

     (d)  Stonegate will act on a best efforts basis and will have no obligation
          to purchase any of the Securities offered in any Placement. During the
          Contract  Period,  Stonegate  shall  have the  non-exclusive  right to
          identify the Purchasers and arrange for all sales of Securities in the
          Placements. All sales of Securities in the Placements shall be subject
          to the approval of the Company,  which approval may be withheld in the
          Company's sole discretion.

2.   CONTRACT PERIOD AND TERMINATION.

     (a)  Stonegate  shall act as the Company's  non-exclusive  placement  agent
          under this  Agreement for a period  commencing on the Effective  Date,
          and continuing until terminated by either Party upon 10 days notice to
          the other Party (the "Contract Period").

     (b)  Upon termination, neither party will have any further obligation under
          this  Agreement,  except as  provided in Sections 5, 6, 7, 8, 9 and 10
          hereof.

3.   REPRESENTATIONS AND WARRANTIES OF THE PARTIES.

     Each of the Parties  represents to the other that (i) it has full power and
     authority  to enter  into this  Agreement  and to perform  its  obligations
     hereunder,  (ii)  this  Agreement  is  enforceable  against  such  Party in
     accordance with its terms, subject to applicable laws governing bankruptcy,
     insolvency  and creditors'  rights  generally and (iii) this Agreement does
     not conflict  with,  violate,  cause a default,  right of  termination,  or
     acceleration  (whether  through the passage of time or otherwise) under any
     contract,  agreement,  or  understanding  binding  upon  such  Party or any
     subsidiary of such Party.

4.   COVENANTS OF THE COMPANY.

     The Company covenants and agrees as follows:

     (a)  Neither the Company  nor any  affiliate  of the Company (as defined in
          Rule 501(b) of  Regulation  D) will sell,  offer for sale,  or solicit
          offers to buy, or  otherwise  negotiate in respect of any security (as
          defined in the Securities Act) of the Company which will be integrated
          with the sale of the Securities and cause the Placement to be a deemed
          a public offering requiring registration under the Securities Act.

     (b)  Any and all filings and  documents  required to be filed in connection
          with or as a result of the  Placements  pursuant  to federal and state
          securities  laws are the  responsibility  of the  Company  and will be
          filed by the  Company,  other  than NASD or other  regulatory  filings
          required to be made by  Stonegate  or a  particular  Purchaser,  which
          shall be the obligation of Stonegate or such Purchaser, as applicable.

     (c)  Any press release to be issued by the Company  announcing or referring
          to any  Placement in which  Stonegate  serves as the  placement  agent
          shall be subject to the prior review of Stonegate,  such review not to
          be unreasonably  withheld or delayed.  Stonegate shall be permitted to
          publish a tombstone or similar  advertisement  upon completion of each
          Placement  identifying  itself as the Company's  placement  agent with
          respect  thereto,  subject  to the prior  review and  approval  of the
          Company,  such review or approval not to be  unreasonably  withheld or
          delayed.  This Agreement shall not be filed publicly by the Company or
          Stonegate  without  the prior  written  consent  of  Stonegate  or the
          Company,   respectively,   unless   required  by  applicable   law  or
          regulation.

                                       2
<PAGE>

5.   FURNISHING OF COMPANY INFORMATION; CONFIDENTIALITY; OTHER MATTERS.

     (a)  In connection with Stonegate's  activities  hereunder on the Company's
          behalf,  the  Company  shall  furnish  Stonegate  with all  reasonable
          information  concerning the Company and its operations  that Stonegate
          deems necessary or appropriate (the "Company  Information")  and shall
          provide  Stonegate  with  reasonable  access to the  Company's  books,
          records, officers, directors, employees,  accountants and counsel. The
          Company  acknowledges  and agrees  that,  in  rendering  its  services
          hereunder,  Stonegate  will be using  and  relying  upon  the  Company
          Information  without independent  verification  thereof or independent
          appraisal  of  any  of the  Company's  assets  and  may,  in its  sole
          discretion,  use additional information contained in public reports or
          other information furnished by the Company or third parties.

     (b)  Stonegate agrees that the Company  Information will be used solely for
          the  purpose of  performing  its  services  hereunder.  Subject to the
          limitations set forth in subsection (c) below, Stonegate will keep the
          Company  Information  provided  hereunder  confidential  and  will not
          disclose such Company  Information or any portion thereof,  except (i)
          to a third party  contacted  by  Stonegate  on behalf of, and with the
          prior  approval of, the Company  pursuant  hereto who has agreed to be
          bound  by  a  confidentiality   agreement  satisfactory  in  form  and
          substance  to the  Company,  or (ii) to any other person for which the
          Company's  consent  to  disclose  such  Company  Information  has been
          obtained.

     (c)  Stonegate's confidentiality obligations under this Agreement shall not
          apply to any portion of the Company  Information which (i) at the time
          of disclosure to Stonegate or thereafter is generally available to and
          known by the public  (other than as a result of a disclosure  directly
          or indirectly by Stonegate in violation of this  Agreement);  (ii) was
          available to Stonegate on a non-confidential basis from a source other
          than the Company,  provided  that such source is not and was not bound
          by a  confidentiality  agreement  with  the  Company;  (iii)  has been
          independently acquired or developed by Stonegate without violating any
          of its  obligations  under this  Agreement;  or (iv) the disclosure of
          which is legally  compelled  (whether  by  deposition,  interrogatory,
          request for documents, subpoena, civil or administrative investigative
          demand or other similar process).  In the event that Stonegate becomes
          legally  compelled  to  disclose  any  of  the  Company   Information,
          Stonegate  shall provide the Company with prompt prior written  notice
          of such requirement so that the Company may seek a protective order or
          other  appropriate  remedy and/or waive  compliance  with the terms of
          this Agreement.  Stonegate further agrees that it shall not buy, sell,
          transfer, make any short sale of, grant an option for the purchase of,
          or enter  into  any  holdings  or  similar  transaction  with the same
          economic  effect as a sale,  with  respect  to any  securities  of the
          Company during such time as it is in possession of material non-public
          Company Information.

                                       3
<PAGE>

     (d)  Stonegate  acknowledges  and agrees  that it will:  (i)  provide  each
          prospective  Purchaser of Securities  only with materials  supplied to
          Stonegate  by the Company or  otherwise  pre-approved  by the Company,
          including,  but not limited to: a  placement  memorandum,  the form of
          stock purchase  agreement and registration  rights agreement and other
          related  agreements  (except that nothing herein shall be construed to
          require  the  Company to approve  customary  email  communications  by
          Stonegate to actual or prospective Purchasers of the Securities), (ii)
          at all times comply with all United States and foreign federal, state,
          local and common laws,  and all rules,  regulations  and orders of any
          court  or   government   agency,   applicable  to  Stonegate  and  the
          performance  of  the  services   hereunder,   (iii)  comply  with  all
          applicable  United  States and foreign  federal  and state  securities
          laws,  (iv) not engage in any acts which  would  cause the  Company to
          lose or forfeit the exemption from  registration  to issue  Securities
          afforded pursuant to Section 4(2) under the Securities Act or Rule 506
          as promulgated  under the Securities Act, and (v) use its commercially
          reasonable  efforts  to  assist  the  Company  in  obtaining  complete
          documentation   from  each  Purchaser  of  Securities   introduced  by
          Stonegate to the Company.

     (e)  The  obligations of the Parties under this Section 5 shall survive the
          termination of this Agreement for 12 months.

6.   FEES AND EXPENSES.

     (a)  As compensation for services  rendered by Stonegate in connection with
          the Placements, the Company agrees to pay Stonegate a fee (the "Agency
          Fee") of seven  percent  (7%) of the gross  proceeds  from the sale of
          Securities  in the  Placements.  In the case of any proceeds  from the
          sale of Securities to those persons or entities listed on Attachment 1
          hereto  (collectively,  the "Excluded  -------------  Purchasers") who
          elect to participate in the Placement, the Company shall pay Stonegate
          an agency fee (the  "Reduced  Agency Fee") equal to three and one-half
          percent  (3.5%) of the gross  proceeds  from the sale of securities to
          such Excluded  Purchasers.  The Agency Fee and the Reduced  Agency Fee
          shall be paid  immediately upon the closing of each sale of Securities
          by the Company.

     (b)  The Company shall also promptly reimburse Stonegate for all reasonable
          out-of-pocket  expenses  incurred  by  Stonegate  and  its  directors,
          officers  and  employees  in  connection   with  the   performance  of
          Stonegate's services under this Agreement,  up to an aggregate maximum
          of  $20,000.  Any  expenses in excess of an  aggregate  of $20,000 for
          which  Stonegate  seeks  reimbursement  from the Company must have the
          prior written  approval of the Company.  Stonegate shall not incur any
          reimbursable  out-of-pocket  expense in excess of $5,000  without  the
          prior  written  consent  of  the  Company,  such  consent  not  to  be
          unreasonably  withheld.  Stonegate  will  notify  the  Company  before
          incurring  any travel for the  Company  and will  endeavor to have the
          Company  direct  billed for any such  travel  costs and  expenses,  as
          practicable.  For  these  purposes,   "out-of-pocket  expenses"  shall
          include,  but not be  limited  to,  attorneys'  fees and  costs,  long
          distance telephone,  facsimile,  courier,  mail, supplies,  travel and
          similar expenses.

                                       4
<PAGE>

     (c)  Upon  closing  of the  Placement,  the  Company  agrees  to  issue  to
          Stonegate  a  Securities   Purchase  Warrant  (the   "Representative's
          Warrant")  entitling  the  holder(s)  thereof to purchase an amount of
          Securities  equal  to  seven  percent  (7%)  of the  total  number  of
          Securities sold in the closing for such Placement  (three and one-half
          percent (3.5%) with respect to Securities sold to Excluded Purchasers)
          for a period of five (5) years at an exercise price per share equal to
          the  price  at  which  the  Securities  are  sold to  Purchasers.  The
          Representative's  Warrants shall be immediately  exercisable  from the
          date of the initial  closing of the  Placement.  The  Representative's
          Warrant  shall  otherwise  be  substantially  in the form of Exhibit A
          attached hereto.

     (d)  The  obligations of the Parties under this Section 6 shall survive the
          termination of this Agreement for any reason.

7.   INDEMNIFICATION.

     (a)  The Company agrees to indemnify and hold  Stonegate  harmless from and
          against  any  and all  losses,  claims,  damages  or  liabilities  (or
          actions, including securityholder actions, in respect thereof) related
          to or arising out of Stonegate's  engagement  hereunder or its role in
          connection  herewith,  and will reimburse Stonegate for all reasonable
          expenses  (including  reasonable costs,  expenses,  awards and counsel
          fees and/or judgments) as they are incurred by Stonegate in connection
          with  investigating,  preparing  for or  defending  any such action or
          claim,  whether  or not  in  connection  with  pending  or  threatened
          litigation  in which  Stonegate  is a party.  The  Company  will  not,
          however, be responsible for any claims,  liabilities,  losses, damages
          or expenses which are finally  judicially  determined to have resulted
          primarily from the bad faith,  gross negligence or willful  misconduct
          of Stonegate.  The Company also agrees that  Stonegate  shall not have
          any  liability  to  the  Company  for  or  in  connection   with  such
          engagement, except for any such liability for losses, claims, damages,
          liabilities or expenses  incurred by the Company that result primarily
          from  the  bad  faith,  gross  negligence  or  willful  misconduct  of
          Stonegate.  In the event that the foregoing  indemnity is  unavailable
          (except by reason of the bad faith or gross  negligence of Stonegate),
          then the  Company  shall  contribute  to  amounts  paid or  payable by
          Stonegate in respect of its losses, claims, damages and liabilities in
          such  proportion  as  appropriately  reflects  the  relative  benefits
          received  by, and fault of, the Company and  Stonegate  in  connection
          with  the  matters  as  to  which  such  losses,  claims,  damages  or
          liabilities relate, and other equitable considerations.  The foregoing
          shall be in addition to any rights that  Stonegate  may have at common
          law or otherwise  and shall extend upon the same terms to and inure to
          the benefit of any director,  officer,  employee, agent or controlling
          person  of  Stonegate.   The  Company  hereby   consents  to  personal
          jurisdiction,  service and venue in any court in which any claim which
          is subject to this agreement is brought against Stonegate or any other
          person  entitled  to   indemnification   or  contribution  under  this
          subsection (a).

     (b)  Stonegate  agrees to indemnify and hold the Company  harmless from and
          against  any  and all  losses,  claims,  damages  or  liabilities  (or
          actions,  including  securityholder actions, in respect thereof) which
          are finally judicially  determined to have resulted primarily from the
          bad faith,  gross negligence or willful  misconduct of Stonegate,  and
          will  reimburse  the Company for all  reasonable  expenses  (including
          reasonable costs, expenses,  awards and counsel fees and/or judgments)
          as they are incurred by the Company in connection with  investigating,
          preparing for or defending any such action or claim, whether or not in
          connection with pending or threatened  litigation in which the Company

                                       5
<PAGE>

          is a party. In the event that the foregoing  indemnity is unavailable,
          then  Stonegate  shall  contribute  to amounts  paid or payable by the
          Company in respect of its losses,  claims,  damages and liabilities in
          such  proportion  as  appropriately  reflects  the  relative  benefits
          received  by, and fault of, the Company and  Stonegate  in  connection
          with  the  matters  as  to  which  such  losses,  claims,  damages  or
          liabilities relate, and other equitable considerations.  The foregoing
          shall be in addition to any rights that the Company may have at common
          law or otherwise  and shall extend upon the same terms to and inure to
          the benefit of any director,  officer,  employee, agent or controlling
          person  of  the  Company.   Stonegate   hereby  consents  to  personal
          jurisdiction, service and venue in any court in which any claim, which
          is subject to this  agreement,  is brought  against the Company or any
          other person entitled to  indemnification  or contribution  under this
          subsection (b).

     (c)  The  obligations of the Parties under this Section 7 shall survive the
          termination of this Agreement.

8.   NON-CIRCUMVENTION.

     The Company  hereby  agrees that,  for a period of one year from the end of
     the Contract  Period or other  termination of this  Agreement,  the Company
     will not enter into any agreement,  transaction or arrangement  with any of
     the institutions (including their agents, principals and affiliates and the
     accounts  and funds  which  they  manage or  advise)  which  Stonegate  has
     introduced  to the  Company  pursuant  to a meeting,  telephone  call,  any
     written  communication,  or by e mail,  as  prospective  purchasers  of the
     Securities in the  Placements,  which at the written request of the Company
     Stonegate  has  identified  to the  Company  in  writing on or prior to the
     termination   of  the  Contract   Period   (collectively,   the  "Stonegate
     Contacts"),  regardless of whether a transaction is  consummated  with such
     prospective purchasers, unless the Company notifies Stonegate in writing of
     the agreement,  transaction or arrangement,  and pays Stonegate a fee equal
     to the Agency Fee for securities of the Company sold to Stonegate Contacts.

9.   GOVERNING LAW.

     THIS  AGREEMENT  SHALL BE CONSTRUED IN ACCORDANCE  WITH AND GOVERNED BY THE
     LAWS OF THE STATE OF TEXAS,  WITHOUT  GIVING EFFECT TO ANY CONFLICT OF LAWS
     PROVISIONS THEREOF.

10.  ARBITRATION.

     Stonegate  and the Company will attempt to settle any claim or  controversy
     arising out of this Agreement through  consultation and negotiation in good
     faith and a spirit of mutual  cooperation.  Any  dispute  which the parties
     cannot resolve may then be submitted by either party to binding arbitration
     in Dallas,  Texas under the rules of the American  Arbitration  Association
     for  resolution.  Nothing in this  paragraph will prevent either party from
     resorting to judicial  proceedings if (a) good faith efforts to resolve the
     dispute under these procedures have been unsuccessful or (b) interim relief
     from a court is necessary to prevent serious and irreparable injury.

                                       6
<PAGE>

11.  NO WAIVER.

     The  failure or neglect of any party  hereto to insist,  in any one or more
     instances, upon the strict performance of any of the terms or conditions of
     this Agreement,  or waiver by any party of strict performance of any of the
     terms or conditions of this  Agreement,  shall not be construed as a waiver
     or  relinquishment  in the future of such term or  condition,  but the same
     shall continue in full force and effect.

12.  SUCCESSORS AND ASSIGNS.

     The benefits of this  Agreement  shall inure to the benefit of the Parties,
     their  respective   successors,   assigns  and  representatives,   and  the
     obligations and liabilities  assumed in this Agreement by the Parties shall
     be binding upon their respective successors and assigns. This Agreement may
     not be assigned by either Party without the express  written consent of the
     other Party, which consent shall not be unreasonably withheld.

13.  NOTICES.

     All notices and other  communications  required  or  permitted  to be given
     under this Agreement shall be in writing and shall be delivered  personally
     or sent by certified mail, return receipt requested,  recognized  overnight
     delivery service, or facsimile as follows:

                   If to the Company:
                   ------------------

                   Intraop Medical Corporation
                   3170 De La Cruz Boulevard
                   Suite 108
                   Santa Clara, California 95054
                   Facsimile: (408) 986-0222
                   Attention: Donald A. Goer, Chief Executive Officer

                   If to Stonegate:
                   ----------------

                   Stonegate Securities, Inc.
                   5940 Sherry Lane, Suite 410
                   Dallas, Texas  75225
                   Facsimile: (214) 987-1981
                   Attention: Scott Griffith, President

     Either Party may change its address or facsimile  number set forth above by
     giving  the other  Party  notice  of such  change  in  accordance  with the
     provisions  of this  Section 13. A notice  shall be deemed  given (a) if by
     personal delivery, on the date of such delivery,  (b) if by certified mail,
     on the date shown on the  applicable  return  receipt,  (c) if by overnight
     delivery  service,  on the day after the date delivered to the service,  or
     (d) if by facsimile, on the date of transmission.

                                       7
<PAGE>

14.  NATURE OF RELATIONSHIP.

     The Parties  intend that  Stonegate's  relationship  to the Company and the
     relationship of each director,  officer,  employee or agent of Stonegate to
     the  Company  shall  be that  of an  independent  contractor  and not as an
     employee of the Company or an affiliate thereof.  Nothing contained in this
     Agreement shall constitute or be construed to be or create a partnership or
     joint  venture  between  Stonegate  and the  Company  or  their  respective
     successors  or  assigns.  Neither  Stonegate  nor  any  director,  officer,
     employee or agent of Stonegate shall be considered to be an employee of the
     Company by virtue of the services provided hereunder.

15.  MISCELLANEOUS

     Stonegate's  obligations  under this Agreement are subject to the following
     general conditions:

     (a)  Stonegate  reserves  the right to solicit  the  assistance  of outside
          dealers ("Dealers") to assist in the offer and sale of the Placements;
          provided,  however, that any such Dealers agree in writing to be bound
          by the  terms  of the  applicable  Placement.  It is  understood  that
          Stonegate,  in its sole  discretion,  shall be entitled to pay over to
          any such Dealers any portion of the compensation received by Stonegate
          hereunder.  The Company shall have no financial liability for any fees
          or expenses of any such Dealers.

16.  CAPTIONS.

     The  Section  titles  herein  are for  reference  purposes  only and do not
     control or affect the meaning or  interpretation  of any term or  provision
     hereof.

17.  AMENDMENTS.

     No  alteration,  amendment,  change or addition  hereto shall be binding or
     effective  unless  the same is set  forth  in a  writing  signed  by a duly
     authorized representative of each Party.

18.  PARTIAL INVALIDITY.

     If it is finally determined that any term or provision hereof is invalid or
     unenforceable,  (a) the  remaining  terms and  provisions  hereof  shall be
     unimpaired, and (b) the invalid or unenforceable term or provision shall be
     replaced  by a term or  provision  that is valid and  enforceable  and that
     comes as close as possible to  expressing  the  intention of the invalid or
     unenforceable term or provision.

19.  ENTIRE AGREEMENT.

     This  Agreement  embodies the entire  agreement  and  understanding  of the
     Parties  and  supersedes  any and all prior  agreements,  arrangements  and
     understandings relating to the matters provided for herein.

20.  COUNTERPARTS.

     This Agreement may be executed in one or more  counterparts,  each of which
     shall be an original, but all of which together shall be considered one and
     the same agreement.

                                       8
<PAGE>

         IN WITNESS  WHEREOF,  this  Agreement  has been executed as of the date
first  written  above by duly  authorized  representatives  of the  Company  and
Stonegate.

                                                     INTRAOP MEDICAL CORPORATION

                                                     By: /s/ Scott Griffith
                                                     Title: President

                                                     STONEGATE SECURITIES, INC.

                                                     By: /s/ Donald A. Goer
                                                     Title: President

                                       9Exhibit 10.9

                               DISCLOSURE SCHEDULE
                               -------------------

         This  Disclosure   Schedule,   dated  as  of  August  31,  2005  (  the
"Schedule"),  is made and given  pursuant  to Article  III and Article IV of the
Securities  Purchase  Agreement dated as of August 31, 2005 by and among Intraop
Medical  Corporation  and the purchasers  named therein (the  "Agreement").  Any
terms  defined in the  Agreement  shall have the same  meaning when used in this
Disclosure  Schedule as when used in the Agreement unless the context  otherwise
requires.

         Notwithstanding  anything to the contrary contained in this Schedule or
in the Agreement,  the information and disclosures  contained in each section of
this Schedule  (including  any  schedules  attached to this  Schedule)  shall be
deemed to be disclosed and  incorporated by reference in each of the sections of
this Schedule as though fully set forth in such other  sections  (whether or not
specific  cross-references are made) where it is reasonably apparent on the face
of the disclosure (without regard to the contents of any document referred to in
such  disclosure and the contents of which are not expressly  described or facts
and circumstances not expressly described or implied in such disclosure) that it
is applicable to such other  sections,  and shall be deemed to qualify and limit
all  representations,  warranties and covenants of the Company  contained in the
Agreement.

Section 3.1(a)(b)

The Company's subsidiaries are:

     1.   Intraop Medical Services, Inc., a Delaware corporation, a wholly owned
          subsidiary. The company is in good standing in Delaware, but is not in
          good standing in California due to failure to pay California franchise
          taxes. The Company is the sole stockholder.

     2.   IMS Louisville, LLC a Delaware limited liability corporation, of which
          the Company is the sole member and manager. IMS Louisville is inactive
          in Delaware, pending dissolution.

Section 3.1(d)(ii)

Unless  certain  waivers or consents are given on or prior to the Closing  Date,
the execution,  delivery,  and  performance of the  Transaction  Documents would
conflict with or constitute a default under:

1. Loan  Agreement  and/or  related  agreements  of March 22,  2004  between the
Company, as successor to Intraop Medical,  Inc., and Samir Financial,  L.L.C., a
Illinois limited liability  company for  $3,000,000.00 of outstanding  principal
(the "Samir Debt"). Interest on this note, at 21.00% per annum, has been prepaid
through September 22, 2005.

                                       1
<PAGE>

2. Section 5(d) of the Note Purchase  Agreement and/or related  agreements dated
March 1, 2002 between the Company,  as successor to Intraop  Medical,  Inc., and
various note holders totaling approximately $480,000.00 of outstanding principal
plus accrued  interest at 9.00% per annum  accruing  from April 1, 2005 (the "PN
Debt").

Section 3.1(g)

1. The  capitalization  of  the  Company  consists  of  100,000,000  shares  of
authorized  common  stock,  $0.001 par  value,  of which  17,733,028  shares are
outstanding.  Included in the outstanding shares are 2,400,000 shares related to
the Samir Debt which will be cancelled  upon  repayment  of that debt.  No other
class of stock is authorized or outstanding.

2. Holders of the PN Debt have the right to convert their notes to shares of the
Company's  common stock at any time and at their sole discretion at a conversion
price of $1.25 per share. However, subject to the close, note holders of PN Debt
shown on Exhibit  4.9(b) have agreed to convert their  outstanding  principal to
Company common stock at $0.70 per share and their  outstanding  interest and the
principal  and interest of the remaining  note holders shown on Schedule  4.9(f)
will be repaid.

3. Holders of the certain  promissory notes executed pursuant to its Convertible
Promissory Note Program in the original  principal amount of $1,370,192.04  plus
accrued  interest,  at 8.00% per annum,  of  $105,433  as of July 31,  2005 (the
"Bridge Debt"), which were due in full at March 31, 2005, but remain outstanding
have the right to convert their notes to shares of the Company's common stock at
any time and at their sole discretion at a conversion  price of $1.50 per share.
However,  subject to the close, Bridge Debt note holders shown on Exhibit 4.9(d)
have agreed to convert  their  outstanding  principal  and interest to shares of
Company  common stock at $0.70 per share while the notes of the  remaining  note
holders shown on Exhibit 4.9(g) will be repaid.

4. The Company has outstanding options  exercisable  1,127,500 for shares of the
Company's  common  stock at prices  ranging  from  $0.10 per share to $1.375 per
share.

5. The Company has outstanding  warrants exercisable for 1,448,174 shares of the
Company's  common stock at exercise prices ranging from $0.52 per share to $2.50
per share.

6. The Company received notices from shareholders representing all 97,000 shares
of common stock who had previously  voted against the Merger that they wished to
redeem their shares in accordance with certain  dissenter's  rights  provisions.
The estimated redemption value is $121,250.

7. The Company is  obligated to issue  certain  warrants  Stonegate  Securities,
Inc., a Texas corporation ("Stonegate"), as described in Section 3.1(s) below.

                                       2
<PAGE>

Section 3.1(i)(ii)

On August 22, 2005 and August 26, 2005, the Company became obligated under notes
in the principal  amount of $187,500 from Donald A. Goer,  its CEO and Chairman.
The notes are  unsecured  and bear interest at 9% per annum and are to be repaid
when the finances of the Company  permit and have not been  disclosed in filings
with the SEC.

Section 3.1(j)

At June 30, 2005,  the Company owed Siemens  Medical  Solutions,  Oncology  Care
Systems   Division,   a  division  of  Siemens   Medical   Solutions  USA,  Inc.
(collectively  "Siemens")  $152,258  (after  including  interest)  (the "Siemens
Debt") due to the termination of the Company's  Manufacturing  and  Distribution
agreement  with  Siemens in October  2002.  In  December  2004,  the Company and
Siemens reached a settlement  agreement  whereby the Company signed an unsecured
note in the amount of $171,185 in full  satisfaction of all outstanding  amounts
due Siemens.  The note was due in full on December 31, 2004. The Company did not
make the payment due on December 31,  2004,  but did,  however,  pay all accrued
interest plus principal in the amount of $21,185 in May 2005.

On June 10, 2005,  Siemens  served the Company with a summons and  complaint for
$144,702.51  outstanding  and  due  under  such  note  plus  costs  incurred  in
connection with enforcing such note.

On July 5, 2005, the Company made principal payments aggregating  $47,742,  plus
accrued interest. On July 14, 2005, Siemens and the Company reached a settlement
with  respect to the balance of  approximately  $102,258  owed by the Company to
Siemens under the note. The parties agreed that the Company will repay such note
in two installments, $50,000 by July 30, 2005 and the balance of the outstanding
principal  and accrued  interest by August 31, 2005.  In  addition,  the Company
entered into a  stipulation  of entry of judgment for such amount plus costs and
Siemens  agreed to forbear  enforcing such judgment so long as the Company makes
the agreed  payments.  The Company did not make the required payment on July 31,
2005.

Section 3.1(l)

The Company is in payment  default under (i) the Siemens Debt,  (ii) the PN Debt
and (iii) the Bridge Debt.

Section 3.1(n)

1. All of the assets of the Company are subject to a lien and security  interest
which secures the Samir Debt.

                                       3
<PAGE>

2.  Pursuant to a  Factoring  Agreement  dated  February  24,  2005  ("Factoring
Agreement") in the principal  amount of $1,060,000,  the Company has pledged its
right,  title and interest in its Mobetron S/N 13 and all  contracts or proceeds
related to the unit, including its contemplated contract for sale of the unit to
the  University  of  Heidleburg,   to  E.U.  Capital  Venture,  Inc.,  a  Nevada
corporation ("EU Venture").

3. In October 2004, the Company entered into an inventory  repurchase  agreement
with a EU Venture (the "First EU Repurchase Agreement").  Under the terms of the
agreement,  EU  Venture  placed  an order  for  Mobetron  S/N 15 (the  "Financed
Mobetron")  with  CDS  Engineering  LLC  ("CDS")  and gave a  deposit  to CDS of
$525,000  towards the purchase of that  Mobetron.  In January 2005,  the Company
entered into an inventory  repurchase  agreement with EU Venture (the "Second EU
Repurchase Agreement").  Under the terms of the agreement, the EU Venture placed
an order for Mobetron S/N 14 (the "Second Financed  Mobetron") with CDS and gave
a deposit to CDS of $540,000  towards the  purchase of that  Mobetron.  In April
2005, the Company entered into an inventory repurchase agreement with EU Venture
(the "Third EU Repurchase Agreement").  Under the terms of the agreement, the EU
Venture  placed an order for a Mobetron S/N 15 (the "Third  Financed  Mobetron")
with the  Company  and gave a deposit to the  Company of  $562,000  towards  the
purchase of that Mobetron.  The Financed Mobetron,  the Second Financed Mobetron
and the Third Financed Mobetron are subject to a lien by EU Venture.

4.  On  August  16,  2005,  the  Company  entered  in to an  Inventory/Factoring
Agreement  with  E.U.C.  Holding  and EU Venture  (the "EU  Line").  The Company
anticipates that inventory and contracts  currently financed under the Factoring
Agreement, the First EU Repurchase Agreement, the Second EU Repurchase Agreement
and the Third EU Repurchase  Agreement will be refinanced  under the EU Line and
be subject to liens under EU Line.

Section 3.1(p)

The  Company's  directors  and  officer's  insurance  coverage  in the amount of
$3,000,000 is less than the anticipated Subscription Amount.

Section 3.1(q)

The Company has entered  into  certain  loan  agreements  with its  officers and
directors as described in Section 3.1(i)(ii) above.

Section 3.1(r)

The  Company  is  in  material  compliance  with  the  disclosure  controls  and
procedures provisions of the Sarbanes-Oxley Act of 2002. The internal accounting
controls  provisions of the Sarbanes-Oxley Act of 2002 are not yet applicable to
the Company and the Company may not be in material with all of such  provisions.
However,  the  Company is working to insure that it is in  compliance  with such
provisions when they become applicable to the Company.

                                       4
<PAGE>

Section 3.1(s)

The Company has  entered  into  Placement  Agency  Agreement  dated May 17, 2005
("Agency  Agreement")  with  Stonegate  under  which  the  consummation  of  the
transactions  contemplated by the  Transaction  Documents are subject to certain
fees and other compensation being paid to Stonegate.

Specifically,  Stonegate is entitled under the agreement to receive,  at closing
of the  contemplated  transactions:(i)  proceeds  equal  7% of the  Subscription
Amount (the "Fee  Amount"),  (ii) a number of  warrants  equal to the Fee Amount
divided by initial  Conversion  Price and which warrant  shall be  substantially
similar in the form of  Exhibit  3.1(s) and (iii)  reimbursement  of  reasonable
out-of-pocket expenses of Stonegate up to an aggregate maximum of $20,000.

Section 3.1(v)

The Company has not granted  registration rights to any parties other than those
to be included on the Company's first registration as set forth on Schedule 6(b)
to the Registration Rights Agreement.

Section 3.1(y)

The Company has  disclosed to  Stonegate,  Bushido  Capital  Master  Fund,  L.P,
Regenmacher  Holdings,  Ltd. and [Gamma]  information  that constitutes or might
constitute material,  nonpublic information pursuant to nondisclosure agreements
executed by such  Purchasers,  including but not limited to,  detailed sales and
manufacturing projections and forecasts,  detailed financial projections,  lists
of holders and their holdings of the Company's  stock,  warrants,  options,  and
debt and accounts payable,  and agreements pursuant to those holdings.  Any such
information that is or might constitute material nonpublic information about the
Company  will not be material or will be publicly  available on or prior to such
date that the Company files its Form 10-KSB for its fiscal year ending September
30, 2005.

Section 3.1(aa)

Except as  disclosed  in Section  3.1(h)  above,  the SEC  Reports set forth all
outstanding secured and unsecured Indebtedness of the Company or any Subsidiary,
or for which the Company or any Subsidiary has commitments.

Section 3.1(ee)

The Company's  certified  public  accountants at the time of the issuance of the
10-KSB for the year ended  December 31, 2004 were Madsen and  Associates  CPA's,
Inc. Subsequent to the Merger, the Company retained Stonefield Josephson,  Inc.,
as its accountants.

                                       5
<PAGE>

Section 3.1(ff)

The Regenmacher  Debenture and certain inventory financing will be senior to the
Debentures upon liquidation or dissolution.

Section 3.1(gg)

As of June 30, 2005 the Company has  outstanding  invoice from DLA Piper Rudnick
Gray  Cary US LLP  ("Gray  Cary")  totaling  approximately  $446,781  for  legal
services.  The Company has asked Gray Cary to adjust its billings to the Company
due to certain disagreements over the invoiced amounts.

Schedule 4.9

A.   The following  Indebtedness will remain outstanding following the close:
     1.   The Convertible Debenture.
     2.   The Senior Secured Debenture.
     3.   To the  extent  not  refinanced  under  the  EU  Line:  the  Factoring
          Agreement, the First EU Repurchase Agreement, the Second EU Repurchase
          Agreement and the Third EU Repurchase Agreement.
     4.   The EU Line.
     5.   Promissory notes shown on Exhibit 4.9(a) and Exhibit 4.9(j).

B. The following  Indebtedness will convert to Company common stock at $0.70 per
share contemporaneous with the close:
     1.   PN Debt principal shown on Exhibit 4.9(b).
     2.   Bridge  Debt  principal  and  approximate  interest  shown on Exhibits
          4.9(c) and 4.9(d).
     3.   Shareholders  advances  from  Robert  Minor  and  John  From  totaling
          $438,000.
     4.   Promissory  note principal and  approximate  interest shown on Exhibit
          4.9(e).

C. The following Indebtedness will be repaid contemporaneous with or immediately
following the close:
     1.   Samir Debt  principal of  $2,500,000  including  accrued  interest and
          fees.
     2.   PN Debt shown on Exhibit 4.9(f) and PN Debt approximate interest shown
          on Exhibit 4.9(b).
     3.   Bridge  Debt  principal  and  approximate  interest  shown on  Exhibit
          4.9(g).
     4.   Promissory  note principal and  approximate  interest shown on Exhibit
          4.9(h).  D. Samir Debt  principal  in the amount of  $500,000  will be
          converted to Convertible Debentures contemporaneous with the close.

E.  Indebtedness  on Exhibit 4.9(i) and (j) will be repaid from the close of any
subsequent funding.

G.  The  remainder  of any  proceeds  may be used for any  legitimate  corporate
purpose including the satisfaction of outstanding trade payables.

                                       6
<PAGE>

              Exhibit 4.9(a) -- Remain Outstanding Following Close
                    Individual Related Party Promissory Notes

<TABLE>
<CAPTION>
                                                                                                  Interest Calculation Dates

                                                                                                     Calc Date         8/31/05
                                                                                                     Last Paid        12/31/01

                                                                                                     Int. Owed
Name                                          Amount      Int. Rate     Note Date  Deposit Date           From         Int Due
------------------------------------ ---------------- -------------- ------------- ------------- -------------- ---------------
<S>                                       <C>                 <C>         <C>  <C>      <C>  <C>       <C>  <C>      <C>
Donald A. Goer                            642,754.60          9.00%       9/30/04       9/30/04        9/30/04       55,127.23
Mary Louise Meurk                         164,670.75          9.00%       9/30/04       9/30/04        9/30/04       14,123.34
Donald A. Goer                             25,000.00          9.00%        6/9/05        6/9/05         6/9/05          513.05
Donald A. Goer                             25,000.00          9.00%       7/22/05       7/22/05        7/22/05          246.58
Donald A. Goer                             60,000.00          9.00%        8/1/05        8/1/05         8/1/05          443.84

------------------------------------ ---------------- -------------- ------------- ------------- -------------- ---------------
Total                                     917,425.35                                                                 70,454.04
==================================== ================ ============== ============= ============= ============== ===============
</TABLE>

                                       7
<PAGE>

             Exhibit 4.9(b) -- Principal Converting to Common Stock
                             PN Debt -- 3rd Parties

<TABLE>
<CAPTION>
                                                                         Interest From           4/1/05
                                                                         Interest Thru          8/31/05

                                                             Note/Repay        Interest

Investor                            Amount        Rate             Date         Through            Days     Interest Due
--------------------------- --------------- ----------- ---------------- --------------- --------------- ----------------
<S>                              <C>             <C>             <C> <C>        <C>  <C>            <C>           <C>
Robert Sharpe                    15,000.00       9.00%           3/1/02         8/31/05             153           565.89
Morton Goulder                   50,000.00       9.00%           3/6/02         8/31/05             153         1,886.30
Allan Martin                     70,000.00       9.00%          3/28/02         8/31/05             153         2,640.82
Richard Ference                  50,000.00       9.00%          5/30/02         8/31/05             153         1,886.30
Peter Carriero                   50,000.00       9.00%          9/11/02         8/31/05             153         1,886.30
George Chung                     50,000.00       9.00%         12/19/02         8/31/05             153         1,886.30
C. Ted Wolf                      50,000.00       9.00%           9/1/03         8/31/05             153         1,886.30

--------------------------- --------------- ----------- ---------------- --------------- --------------- ----------------
Total                           335,000.00                                                                     12,638.22
=========================== =============== =========== ================ =============== =============== ================
</TABLE>

                                       8
<PAGE>

       Exhibit 4.9(c) -- Principal and Interest Converting to Common Stock
                          Bridge Notes -- Related Party

<TABLE>
<CAPTION>
                                                                                            From                      1/1/03
                                                                                            Through                  8/31/05

                                                                         Invest/Repay
Investor                  Amount       Rate         Note Date                    Date            Days           Interest Due
--------------------------------- ---------- ----------------- ----------------------- --------------- ----------------------
<S>                    <C>            <C>             <C>  <C>                <C>  <C>            <C>               <C>
Donald Goer            25,000.00      8.00%           1/12/04                 1/12/04             598               3,276.71
Donald Goer            75,000.00      8.00%           1/19/05                 1/19/05             225               3,698.63

--------------------------------- ---------- ----------------- ----------------------- --------------- ----------------------
Total                 100,000.00                                                                                    6,975.34
================================= ========== ================= ======================= =============== ======================
</TABLE>

                                       9
<PAGE>

       Exhibit 4.9(d) -- Principal and Interest Converting to Common Stock
                            Bridge Notes -- 3rd Party

<TABLE>
<CAPTION>
                                                                                                 From                   1/1/03
                                                                                                 Through               8/31/05

                                                                                   Invest/Repay
Investor                                     Amount       Rate     Note Date               Date         Days      Interest Due
---------------------------------- ----------------- ---------- ------------- ------------------ ------------ -----------------
<S>                                      <C>             <C>        <C>   <C>          <C>   <C>         <C>         <C>
Ronald W. Minor                          251,250.00      8.00%      10/21/03           10/21/03          681         37,501.64
Elva L. Rust TR                            5,000.00      8.00%       1/21/04            1/22/04          588            644.38
S. Mitchell Harmon                        25,000.00      8.00%       2/10/04            2/10/04          569          3,117.81
Fredrick Naftolin                         25,000.00      8.00%       2/12/04            2/12/04          567          3,106.85
Barbara Bodine                            10,000.00      8.00%        3/5/04             3/5/04          545          1,194.52
Chiyoda Technol                           91,530.00      8.00%       4/15/04            4/15/04          504         10,110.93
Huub van Roosmalen                        20,000.00      8.00%       4/20/04            4/20/04          499          2,187.40
Schonberg Research Corporation            63,918.33      8.00%       5/31/04            5/31/04          458          6,416.35
Edward S. Sternick                        99,156.21      8.00%        6/9/04             6/9/04          449          9,758.06
KAS Associates                            15,000.00      8.00%       10/1/04            10/1/04          335          1,101.37
Ronald W. Minor                          282,500.00      8.00%      12/28/04           12/28/04          247         15,293.70
Freidrichs                                 1,837.50      8.00%       1/22/05            1/22/05          222             89.41
Eugene Lin                                25,000.00      8.00%       2/10/05            2/10/05          203          1,112.33
Schonberg Research Corporation            90,000.00      8.00%       2/10/05            2/10/05          203          4,004.38
Schonberg Family Trust                    25,000.00      8.00%       2/22/05            2/22/05          191          1,046.58
Richard Supan IRA                         25,000.00      8.00%        3/8/05             3/8/05          177            969.86
Ronald W. Minor                          100,000.00      8.00%       3/10/05            3/10/05          175          3,835.62
Richard Ference                           30,000.00      8.00%       3/10/05            3/10/05          175          1,150.68
Jay Bhatt Trust                           25,000.00      8.00%       3/24/05            3/24/05          161            882.19

---------------------------------- ----------------- ---------- ------------- ------------------ ------------ -----------------
Total                                  1,210,192.04                                                                 103,524.06
================================== ================= ========== ============= ================== ============ =================
</TABLE>

                                       10
<PAGE>

       Exhibit 4.9(e) -- Principal and Interest Converting to Common Stock
                     Individual Third Party Promissory Notes

<TABLE>
<CAPTION>
                                                                                     Interest Calculation     Dates
                                                                                         Calc Date             8/31/05
                                                                                         Last Paid             12/31/01

                                                                                                     Int. Owed
Name                                          Amount      Int. Rate     Note Date  Deposit Date           From         Int Due
------------------------------------ ---------------- -------------- ------------- ------------- -------------- ---------------
<S>                                        <C>                <C>         <C>  <C>      <C>  <C>       <C>  <C>         <C>
Schonberg Family Trust                     41,270.25          9.00%       8/16/05       8/16/05        8/16/05          152.64

------------------------------------ ---------------- -------------- ------------- ------------- -------------- ---------------
Total                                      41,270.25                                                                    152.64
==================================== ================ ============== ============= ============= ============== ===============
</TABLE>

                                       11
<PAGE>

                      Exhibit 4.9(f) -- Repay from Proceeds
                             PN Debt -- 3rd Parties

<TABLE>
<CAPTION>
                                                                Interest From          4/1/05
                                                                Interest Thru         8/31/05

                                                    Note/Repay       Interest

Investor                  Amount      Rate                Date        Through            Days     Interest Due
----------------- --------------- --------- ------------------- -------------- --------------- ----------------
<S>                    <C>           <C>                <C> <C>       <C>  <C>            <C>           <C>
Robert Sharpe          15,000.00     9.00%              3/1/02        8/31/05             153           565.89
James Lynch            50,000.00     9.00%             3/28/02        8/31/05             153         1,886.30
Marie Carriero         80,000.00     9.00%             5/23/03        8/31/05             153         3,018.08

----------------- --------------- --------- ------------------- -------------- --------------- ----------------
Total                 145,000.00                                                                      5,470.27
================= =============== ========= =================== ============== =============== ================
</TABLE>

                                       12
<PAGE>

                      Exhibit 4.9(g) -- Repay from Proceeds
                            Bridge Notes -- 3rd Party

<TABLE>
<CAPTION>
                                                                                             From                       1/1/03
                                                                                             Through                   8/31/05

                                                                               Invest/Repay

Investor                             Amount      Rate        Note Date                 Date           Days        Interest Due
---------------------------- --------------- --------- ---------------- -------------------- -------------- -------------------
<S>                               <C>           <C>           <C>   <C>             <C>  <C>           <C>            <C>
C&C Nuclear Systems               10,000.00     8.00%         4/28//04              4/28/04            491            1,076.16
Carl Hsu                          50,000.00     8.00%         11/16/04             11/16/04            289            3,167.12

---------------------------- --------------- --------- ---------------- -------------------- -------------- -------------------
Total                             60,000.00                                                                           4,243.29
============================ =============== ========= ================ ==================== ============== ===================
</TABLE>

                                       13
<PAGE>

                      Exhibit 4.9(h) -- Repay from Proceeds
                    Individual Related Party Promissory Notes

<TABLE>
<CAPTION>
                                                                                            Interest Calculation Dates
                                                                                            Calc Date         8/31/05
                                                                                            Last Paid        12/31/01

                                                                                            Int. Owed
Name                                 Amount      Int. Rate     Note Date  Deposit Date           From         Int Due
--------------------------- ---------------- -------------- ------------- ------------- -------------- ---------------
<S>                              <C>                 <C>         <C>  <C>      <C>  <C>       <C>  <C>         <C>
Donald A. Goer                   160,000.00          9.00%       8/22/05       8/22/05        8/22/05          355.07
Donald A. Goer                    27,500.00          9.00%       8/26/05       8/26/05        8/26/05           33.90

--------------------------- ---------------- -------------- ------------- ------------- -------------- ---------------
Total                            187,500.00                                                                    388.97
=========================== ================ ============== ============= ============= ============== ===============
</TABLE>

                                       14
<PAGE>

                  Exhibit 4.9(i) -- Repay from Subsequent Close
                     Individual Third Party Promissory Notes

<TABLE>
<CAPTION>
                                                                                           Interest Calculation Dates
                                                                                              Calc Date         8/31/05
                                                                                              Last Paid        12/31/01

                                                                                              Int. Owed
Name                                   Amount      Int. Rate     Note Date  Deposit Date           From         Int Due
----------------------------- ---------------- -------------- ------------- ------------- -------------- ---------------
<S>                                 <C>                <C>         <C>  <C>      <C>  <C>      <C>   <C>      <C>
Jerome Vaeth                        50,000.00          9.00%       9/30/95       9/30/95       12/31/01       19,471.04

----------------------------- ---------------- -------------- ------------- ------------- -------------- ---------------
Total                               50,000.00                                                                 19,471.04
============================= ================ ============== ============= ============= ============== ===============
</TABLE>

                                       15
<PAGE>

                  Exhibit 4.9(j) -- Repay from Subsequent Close
                    Individual Related Party Promissory Notes

<TABLE>
<CAPTION>
                                                                                        Interest Calculation Dates
                                                                                           Calc Date         8/31/05
                                                                                           Last Paid        12/31/01

                                                                                           Int. Owed
Name                                Amount      Int. Rate     Note Date  Deposit Date           From         Int Due
-------------------------- ---------------- -------------- ------------- ------------- -------------- ---------------
<S>                              <C>                <C>         <C>  <C>      <C>  <C>       <C>  <C>       <C>
Donald A. Goer                   70,000.00          9.00%       5/31/05       5/31/05        5/31/05        1,599.79
Donald A. Goer                   30,000.00          9.00%       6/30/05       6/30/05        6/30/05          460.32
Mary Louise Meurk                10,000.00          9.00%       7/21/05       7/21/05        7/21/05          101.10
John Matheu                       5,000.00          9.00%       7/28/05       7/28/05        7/28/05           41.92
Ted Phillips                      5,000.00          9.00%        8/1/05        8/1/05         8/1/05           36.99

-------------------------- ---------------- -------------- ------------- ------------- -------------- ---------------
Total                           120,000.00                                                                  2,240.10
========================== ================ ============== ============= ============= ============== ===============
</TABLE>

                                       16
<PAGE>

                 SCHEDULE 6(b) to REGISTRATION RIGHTS AGREEMENT

         This Schedule 6(b), dated as of August 31, 2005 ( the  "Schedule"),  is
made and given  pursuant to Article 6(b) of the  Registration  Rights  Agreement
dated as of August 31, 2005 by and among  Intraop  Medical  Corporation  and the
purchasers named therein (the  "Agreement").  Any terms defined in the Agreement
shall have the same meaning when used in this  Disclosure  Schedule as when used
in the Agreement unless the context otherwise requires.

         The Company Initial Registration will include:

1. All of the Company's outstanding common stock except 445,000 shares issued to
Summit Financial Partners,  L.L.C or its employees or affiliates pursuant to the
close of the Company's merger on March 9, 2005.

2. Shares of Mr. John From to the extent of his conversion of a prior investment
of $416,000 into the Company's common stock at $0.70 per share.

3.  Shares  of Mr.  Robert  Minor to the  extent  of his  conversion  of a prior
investment of $22,000 into the Company's common stock at $0.70 per share.

4. PN Debt  holders  shown on Exhibit  4.9(b) to the  Purchase  Agreement to the
extent of their conversion into common stock.

5.  Bridge  Debt  holders  shown on Exhibit  4.9(c)  and 4.9(d) to the  Purchase
Agreement to the extent of their conversion into common stock.

6. Promissory note holders shown on Exhibit 4.9(e) to the Purchase  Agreement to
the extent of their conversion into common stock.

7. Holders of  outstanding  warrants  exercisable  for  1,448,174  shares of the
Company's common stock.

8.  Holders  of  outstanding  options  exercisable  1,127,500  for shares of the
Company's common stock.

9. Samir  Financial,  L.L.C., a Illinois limited  liability  company,  for up to
2,400,000  shares of the  Company's  common stock to the extent these shares are
not cancelled as part of the close.

10. Stonegate Securities,  Inc., a Texas corporation ("Stonegate") as the holder
of warrants for shares of the  Company's  common stock  granted in relation to a
Placement Agreement between Stonegate and the Company dated May 17, 2005.

11. The Company has received lock-up agreements pursuant to Section 2.3(b)(v) of
the Securities Purchase Agreement from the parties shown on Exhibit A.

<PAGE>

                           EXHIBIT A TO SCHEDULE 6(b)

WR Hambrecht + Company
Donald A. Goer
Hans Morkner
Richard Supan (due prior to second close)
Russell G. Schonberg
Schonberg Research Corporation
Mary Louise Meurk Pollaczek
Ronald Haynes
Wayne Gianotti
Carl Outzen
Cinnabar Investments
Ronald Minor
John From
Richard From

<PAGE>

                               DISCLOSURE SCHEDULE
                               -------------------

         This  Disclosure   Schedule,   dated  as  of  August  31,  2005  (  the
"Schedule"),  is made  and  given  pursuant  to  Article  III of the  Subsidiary
Guarantee  dated as of  August  31,  2005 by and among  the  Guarantors  and the
Purchasers named therein (the  "Agreement").  Any terms defined in the Agreement
shall have the same meaning when used in this  Disclosure  Schedule as when used
in the Agreement unless the context otherwise requires.

         Notwithstanding  anything to the contrary contained in this Schedule or
in the Agreement,  the information and disclosures  contained in each section of
this Schedule  (including  any  schedules  attached to this  Schedule)  shall be
deemed to be disclosed and  incorporated by reference in each of the sections of
this Schedule as though fully set forth in such other  sections  (whether or not
specific  cross-references are made) where it is reasonably apparent on the face
of the disclosure (without regard to the contents of any document referred to in
such  disclosure and the contents of which are not expressly  described or facts
and circumstances not expressly described or implied in such disclosure) that it
is applicable to such other  sections,  and shall be deemed to qualify and limit
all  representations,  warranties and covenants of the Company  contained in the
Agreement.

Section 3(a)

1. Intraop Medical Services,  Inc., a Delaware corporation,  is in good standing
in Delaware,  but is not in good  standing in  California  due to failure to pay
California franchise taxes. The Company is the sole stockholder.

2. IMS Louisville, LLC a Delaware limited liability corporation,  is inactive in
Delaware, pending dissolution.

Section 3(c)

Unless  certain  waivers or consents are given on or prior to the Closing  Date,
the execution,  delivery,  and  performance of the  Transaction  Documents would
conflict with or constitute a default under certain agreements  described in the
Section  3.1(d)(ii)  of  the  Disclosure  Schedule  to the  Securities  Purchase
Agreement.

Section 3(d)

The Company is in payment  default  under  certain  agreements  described in the
Section 3.1(l) of the Disclosure Schedule to the Securities Purchase Agreement.

<PAGE>

                               DISCLOSURE SCHEDULE

         This Schedule,  dated as of August 31, 2005 ( the "Schedule"),  is made
and given pursuant to Article 3 of the Security Agreement dated as of August 31,
2005 by and among Intraop Medical Corporation and all of the Subsidiaries of the
Company and the Secured  Parties  named  therein  (the  "Agreement").  Any terms
defined  in the  Agreement  shall  have  the  same  meaning  when  used  in this
Disclosure  Schedule as when used in the Agreement unless the context  otherwise
requires.

         Notwithstanding  anything to the contrary contained in this Schedule or
in the Agreement,  the information and disclosures  contained in each section of
this Schedule  (including  any  schedules  attached to this  Schedule)  shall be
deemed to be disclosed and  incorporated by reference in each of the sections of
this Schedule as though fully set forth in such other  sections  (whether or not
specific  cross-references are made) where it is reasonably apparent on the face
of the disclosure (without regard to the contents of any document referred to in
such  disclosure and the contents of which are not expressly  described or facts
and circumstances not expressly described or implied in such disclosure) that it
is applicable to such other  sections,  and shall be deemed to qualify and limit
all  representations,  warranties and covenants of the Company  contained in the
Agreement.

Section 4(h)(ii)

Unless  certain  waivers or consents are given on or prior to the Closing  Date,
the execution,  delivery,  and  performance of the  Transaction  Documents would
conflict with or constitute a default under certain agreements  described in the
Section  3.1(d)(ii)  of  the  Disclosure  Schedule  to the  Securities  Purchase
Agreement.

Section 4(u)

3. Intraop Medical Services,  Inc., a Delaware corporation,  is in good standing
in Delaware,  but is not in good  standing in  California  due to failure to pay
California franchise taxes. The Company is the sole stockholder.

4. IMS Louisville, LLC a Delaware limited liability corporation,  is inactive in
Delaware, pending dissolution.

Section 4(x)

The  Company  is  negotiating  a lease for  relocation  of its  chief  executive
offices,  expected  to  occur  within  the next 30 day to:  570 Del Rey  Avenue,
Sunnyvale CA 94085

<PAGE>

                                   SCHEDULE A

The  books of  account  and  records  of the  Company  are or may be kept at the
following locations:

Intraop Medical Corporation
3170 De La Cruz Blvd. Suite 108
Santa Clara CA 95054

Intraop Medical Corporation
570 Del Rey Avenue
Sunnyvale CA 94085

Corovan
2311 Kruse Drive
San Jose CA 95131

Collateral is or may be stored at the following locations:

Primary Locations                               Sales or Service Offices

Intraop Medical Corporation                     Chapple Musselwhite
3170 De La Cruz Blvd. Suite 108                 Intraop Medical Corporation.
Santa Clara CA 95054                            919 Curtis Drive
                                                Arlington, TX 76012
Intraop Medical Corporation
570 Del Rey Avenue                              Peter Yu
Sunnyvale CA 94085                              Intraop Medical Corporation.
                                                5235 Ruette De Mar
Intraop Medical Corporation                     San Diego CA 92103
27206 Calaroga Avenue, Suite116
Hayward CA 94545                                Michael Ancell
                                                Intraop Medical Corporation.
CDS Engineering LLC                             248 Secret Way
4415 Technology Drive                           Casselberry FL 32707
Fremont CA 94538

Accuray Incorporated
1383 Shorebird Way
Mountain View CA 94043

Corovan
2311 Kruse Drive
San Jose CA 95131

<PAGE>

                                   SCHEDULE B

The assets of the Company are subject to a liens and  security  interests  which
are  further  described  in Section  3.1(n) to the  Disclosure  Schedule  to the
Securities Purchase Agreement.

<PAGE>

                                   SCHEDULE E

Intraop Medical  Corporation was organized under the laws of the State of Nevada
on November 5, 1999 under the name DigitalPreviews.com. On January 21, 2004, the
Company filed a Certificate  of Amendment  with the Secretary of State of Nevada
to change the name of the  Company  from  DigitalPreviews.com,  Inc.  to Intraop
Medical Corporation.

On February 24, 2004,  the Company  signed a  definitive  agreement  and plan of
reorganization   (the  "Merger   Agreement")  with  Intraop  Medical,   Inc.,  a
privately-held  Delaware corporation (the "Target") under which the Target would
be merged with and into the Company in a tax-free  exchange of stock.  Under the
Merger  Agreement,  the  Company  would  issue one share of its common  stock in
exchange for each share of the Target outstanding shares of common and preferred
stock  on  the  closing  date  of the  proposed  merger.  All  of  the  Target's
obligations under its outstanding options,  warrants, and convertible securities
were to be assumed by the Company.

The Board of Director's of the Company approved the merger on February 24, 2004,
the  Target's  Board of Directors  approved the merger on February 12, 2004.  In
addition,  the merger was  approved by the  Company's  majority  stockholder  on
September 3, 2004, and by the Target's stockholders on July 13, 2004. The merger
was  consummated  on  March  9,  2005  as  considerations  for the  merger  were
exchanged.

<PAGE>

                                   SCHEDULE G

                            Intentionally left blank.

<PAGE>

                                   SCHEDULE F

The Company has the  following  registered  the  following  trademarks  with the
United States Patent and Trademark Office:

Trademark               Registration Date          U.S. Reg. Number
------------------------------------------------------------------------------
Mobetron                Feb. 27, 2001              2,432,157
Intraop Medical         Jan. 1, 2002               2,526,210

The Company is the registered owner of the domain name "intraopmedical.com".

                        Schedule continued on next page.

<PAGE>

                             SCHEDULE F (CONTINUED)

The Company maintains the following patent portfolio:

Docket No.       Country             Patent No.    Serial No.
---------------- ------------------- ------------- ---------------------------
OP 105           U.S.                5,321,271     08/040115

                 PCT filed
                 nationals                         PCT/US94/02144
                 Europe              700578        94911427.6
                 Grt Brit            700578        same
                 France              700578        same
                 Germany             700578        same
                 Italy               700578        same
                 Russia              2142827       PCT/US94/02144
                 Japan               2,588,480     Heisei 6 (1994)-522065

---------------- ------------------- ------------- ---------------------------
OP 124 (cont.    U.S.                5,418,372     08/258,569
of Op 105)

---------------- ------------------- ------------- ---------------------------
OP 135           U.S.                5,661,377     08/390,122

                 Europe              811307         96906476.5
                 Grt Britain         811307         same
                 France              811307         same
                 Germany             811307         same

                 Japan                              Heisei8(1996)-525153

                 Russia              2163060        9711557

---------------- ------------------- ------------- ---------------------------
OP 146           U.S.                6,078,036     08/942334

                 PCT                               PCT/US99/09364
                 EU                                999201676

                 Japan                             2000-546663
                 Russia              2230492       2000/27708

================ =================== ============= ===========================

Issue Date    Title of the Patent or Application                      Inventor
------------- ------------------------------------------------------- ----------
6/14/94       Intraoperative Electron Beam Therapy System & Facility  Schonberg

10/17/01      same                                                    same
same          same                                                    same
same          same                                                    same
same          same                                                    same
same          same                                                    same
1999          same                                                    same
7/25/97       same                                                    same

------------- ------------------------------------------------------- ----------
5/23/95       Intraoperative Electron Beam Therapy System & Facility  Schonberg

------------- ------------------------------------------------------- ----------
8/26/97       Microwave Power Control Apparatus For Linear            Mishlin

2005          same                                                    same
same          same                                                    same
same          same                                                    same
same          same                                                    same

              same                                                    same

2/10/05       same                                                    same

------------- ------------------------------------------------------- ----------
6/20/00       Laser Soft Docking System for Medical Treatment System  Cook

              same                                                    same

              same                                                    same
6/20/04       same                                                    same

============= ======================================================= ==========

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]